Head-To-Head Intra-Class Efficacy Trials Urged By FDA’s Temple
This article was originally published in The Tan Sheet
Executive Summary
Drugs with potential safety concerns could benefit from demonstrating an efficacy advantage over other members of the same class, FDA Center for Drug Evaluation & Research Office of Medical Policy Director Robert Temple suggested June 28